Biocon rose 3.10% to Rs 326.35 after the company's subsidiary Biocon Biologics signed a settlement and license agreement with Regeneron, paving the way to commercialize Yesafili, a biosimilar to EYLEA ...

The US Food and Drug Administration (FDA) has approved bevacizumab-nwgd (Jobevne, Biocon Biologics Ltd), a biosimilar to bevacizumab (Avastin, Genentech), for intravenous use across multiple cancer ...

Celltrion, a major Korean biopharmaceutical firm, said Monday it has obtained an interchangeability approval for its ...

Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory ...

Biocon Biologics has gained approval from the US Food and Drug Administration (FDA) for the intravenous use of Jobevne ...

Biocon Biologics' Jobevne, a biosimilar of Avastin, approved by the FDA, expanding oncology portfolio and access to ...

Current observations and foresight into the world of biosimilars, GLP-1s, PBM and payer trends, according to Jeff Casberg, MS ...

A FDA generic drug office was eliminated — and the implications will be felt not only by drugmakers, but consumers ...

In Regeneron Pharms., Inc. v. Mylan Pharms. Inc., the Federal Circuit recently held that biosimilar pharmaceutical companies that filed ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

(Biosimilars are drugs deemed interchangeable with brand-name drugs that are biologically active.) Such approvals save ...